CA
REGN icon

Clearstead Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Clearstead Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$876K Buy
1,134
+26
+2% +$19.9K 0.01% 558
2025
Q4 		$856K Buy
1,108
+223
+25% +$151K 0.01% 516
2025
Q3 		$498K Buy
885
+446
+102% +$252K 0.01% 629
2025
Q2 		$230K Sell
439
-112
-20% -$62.5K ﹤0.01% 850
2025
Q1 		$349K Buy
551
+41
+8% +$28.2K 0.01% 666
2024
Q4 		$363K Buy
510
+29
+6% +$24.3K 0.01% 663
2024
Q3 		$506K Sell
481
-23
-5% -$25.6K 0.01% 568
2024
Q2 		$530K Buy
504
+71
+16% +$68.8K 0.01% 525
2024
Q1 		$423K Sell
433
-46
-10% -$43.7K 0.02% 334
2023
Q4 		$421K Sell
479
-445
-48% -$366K 0.02% 339
2023
Q3 		$760K Buy
924
+445
+93% +$350K 0.02% 345
2023
Q2 		$344K Buy
479
+25
+6% +$19.3K 0.02% 345
2023
Q1 		$373K Buy
454
+128
+39% +$96.5K 0.03% 306
2022
Q4 		$235K Buy
326
+27
+9% +$19.9K 0.02% 359
2022
Q3 		$206K Hold
299
– – 0.02% 357
2022
Q2 		$177K Hold
299
– – 0.01% 395
2022
Q1 		$209K Hold
299
– – 0.01% 401
2021
Q4 		$189K Buy
299
+217
+265% +$133K 0.01% 406
2021
Q3 		$50K Hold
82
– – ﹤0.01% 613
2021
Q2 		$46K Sell
82
-22
-21% -$11.1K ﹤0.01% 574
2021
Q1 		$49K Buy
104
+35
+51% +$17K ﹤0.01% 549
2020
Q4 		$33K Buy
69
+2
+3% +$1.08K ﹤0.01% 567
2020
Q3 		$38K Buy
67
+15
+29% +$9.1K ﹤0.01% 504
2020
Q2 		$32K Hold
52
– – ﹤0.01% 478
2020
Q1 		$25K Buy
+52
New +$21.4K ﹤0.01% 484

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Clearstead Advisors's REGN Position: Q1 2026 in Review

Clearstead Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q1 2026, buying an estimated $19.9K and bringing the position to 1,134 shares worth $876K. The position accounts for 0.01% of the portfolio, ranked #558.

Clearstead Advisors first reported a position in REGN in Q1 2020 and has held it in 25 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Clearstead Advisors held 1,134 shares of Regeneron Pharmaceuticals worth $876K as of Q1 2026.
  • Clearstead Advisors bought 26 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $19.9K.
  • Regeneron Pharmaceuticals made up 0.01% of Clearstead Advisors's portfolio in Q1 2026, its #558 holding.
  • Clearstead Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.